/

Harrow, Inc.

HROW US

HROW USHarrow, Inc.

United States Composite

10.64

USD

+0.24

(+2.31%)

-0.46EPS Dil.

-23.02P/E

373.66MMarket Cap

Next Earnings

March 21

Held by Insiders

12.78%

Held by Institutions

72.55%

Short % of Float

13.94%

YTD Yield

-44.79%

3Y Yield

84.35%

5Y Yield

210.77%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

LT Borrowings

169

170

182

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

636

576

505

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

110

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

28.57%

23.61%

Net Income, GAAP

-NaN%

22.22%

Free Cash Flow

-62.65%

-74.91%

45.45%

Total Cash Common Dividend

- -

-NaN%

Total Equity

-3.16%

165.51%

145.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.01

-0.11

-0.31

-0.27

-0.69

2022

-0.09

-0.23

-0.24

0.04

-0.51

2023

-0.22

-0.14

-0.13

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

0.00

2022

- -

2023

- -

Company Description

CEO: Mr. Mark L. Baum J.D.
Full Time Employees: 217
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: 102 Woodmont Boulevard Nashville TN United States 37205
Website: www.harrow.com
Business: Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Company Description

CEO: Mr. Mark L. Baum J.D.
Full Time Employees: 217
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: 102 Woodmont Boulevard Nashville TN United States 37205
Website: www.harrow.com
Business: Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.